Recent News

• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 05.28.2025 - Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.28.2025 - Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.14.2025 - Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
• 05.14.2025 - Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
• 03.28.2025 - FDA Issues Complete Response Letter for Etripamil for PSVT
• 03.28.2025 - FDA Issues Complete Response Letter for Etripamil for PSVT
• 03.20.2025 - Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
• 03.20.2025 - Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Recent Filings

• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 04.30.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2025 - DEF 14A Other definitive proxy statements
• 04.30.2025 - ARS Annual Report to Security Holders
• 04.30.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.22.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.28.2025 - EX-99.1 EX-99.1
• 03.28.2025 - 8-K Current report